Clinical Trials in Tennessee

Showing 4741-4760 of 20,239 trials

A Study to Evaluate the Safety and Tolerability of Maximal Use Ruxolitinib Cream

NCT06213831

This study is being conducted to determine the safety and tolerability of ruxolitinib 1.5% cream under maximal use conditions in participants with Prurigo Nodularis (PN).

Prurigo Nodularis

Incyte Corporation23 participantsStarted Feb 2024

Phoenix, Arizona, United States • Scottsdale, Arizona, United States • Fountain Valley, California, United States +17 more locations

COMPLETEDPhase 229 miles

COVID19 SARS Vaccinations: Systemic Allergic Reactions to SARS-CoV-2 Vaccinations

NCT04761822

Background: Allergic reactions have been reported to occur after vaccination with both the Pfizer-BioNTech COVID-19 Vaccine and Moderna COVID-19 Vaccine. Allergic reactions range from mild to severe and include life- threatening anaphylactic reactions, although no deaths have been reported with either vaccine. This study is designed with two principal aims: * To estimate the proportions of systemic allergic reactions to the Pfizer-BioNTech COVID-19 Vaccine and the Moderna COVID-19 Vaccine in a High-Allergy/Mast Cell Disorder (HA/MCD) population, and * If the risk in the HA/MCD is demonstrable, to determine whether the proportions are higher in the HA/MCD in comparison to a representative population without severe allergies or mast cell disorders

SARS-CoV InfectionCOVID-19Allergic Reaction+1 more

National Institute of Allergy and Infectious Diseases (NIAID)746 participantsStarted Apr 2021

Tucson, Arizona, United States • Little Rock, Arkansas, United States • Los Angeles, California, United States +26 more locations

A Study to Evaluate the Safety and Tolerability of Maximal Use Ruxolitinib Cream

COVID19 SARS Vaccinations: Systemic Allergic Reactions to SARS-CoV-2 Vaccinations

Find Trials by Condition in Tennessee

A Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME

Integrated Services for Pain: Interventions to Reduce Pain Effectively

Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases

Long Term Extension Study of Tapinarof Cream, 1% for Subjects With Atopic Dermatitis

A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors

A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors

Study of SAR447537 (INBRX-101) Compared to Plasma-derived A1PI Therapy in Adults With AATD Emphysema

To Assess the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa

Study of ORIC-944 in Patients With Metastatic Prostate Cancer

A Study to Assess Adverse Events and Change in Disease Condition of Mesalamine Capsules in Children Aged 5 to 17 Years With Ulcerative Colitis

Observation Study in Patients Age 0-5 Years With LAMA2-related Congenital Muscular Dystrophy

Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance

The MOOD Study - External Combined Occipital and Trigeminal Nerve Stimulation (eCOT-NS) for the Treatment of Major Depressive Disorder (MDD)

A Study of Ad-RTS-hIL-12 With Veledimex in Combination With Nivolumab in Subjects With Glioblastoma; a Substudy to ATI001-102

Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC

A First-in-Human Open-label, Phase I/Ib Dose Escalation and Expansion Cohort Study of EOS006215 as Monotherapy and in Combination With Pembrolizumab or Other Anticancer Treatments in Participants With Advanced Solid Tumors

Proton Beam Radiotherapy for Medulloblastoma and Pineoblastoma

FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery